Page 8«..78910..2030..»

The HCG Diet: What Is It and Does It Work? – Everyday Health

Posted: March 11, 2024 at 2:43 am

The diet requires that you eat only 500 calories a day, supposedly as part of an effort to help reset your metabolism and change your abnormal eating patterns, as the FDA explainsin its warning against the diet. (1) The HCGdiet also requires you to take a daily dose of the hormone human chorionic gonadotropin (HCG). Available in injections, pellets, sprays, oral drops, and pills, HCGis the hormone produced by the placenta during pregnancy.

In 1954, British physician A.T.W. Simeons theorized that HCGallows mothers-to-be to access fat reserves to feed their fetuses. He published a book,Pounds and Inches: A New Approach to Obesity,in which he suggested that HCGcould help people access their fat reserves and achieve weight loss.

The idea might have been that, if a woman had morning sickness or some other condition that prevented her from taking in ample nutrition at a certain point in her pregnancy, her baby would still have a reserve of energy to draw on, and the hormone HCGcould help facilitate access to that supply, Weinandy says. But, she notes, this really oversimplifies the numerous systems at work in pregnancy: A number of hormones are active, and the way they interact can sometimes even promote fat gain for the mother.

In fact, Weinandy says, this kind of speculation about HCGs role in weight loss can be really dangerous, and its sending a bad message to people because we dont know for certain how HCGworks. Another worry? Many chronic diseases, including breast cancer and prostate cancer, have been linked to an imbalance of hormones, so we cant predict what effects manipulating our hormones might have, Weinandy cautions.

See the article here:
The HCG Diet: What Is It and Does It Work? - Everyday Health

Posted in HCG Diet | Comments Off on The HCG Diet: What Is It and Does It Work? – Everyday Health

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Posted: March 1, 2024 at 2:45 am

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients; initial data build on the dose-escalation data featured in a poster presentation at the American Society of Hematology (ASH) Annual Meeting –

Originally posted here:
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Posted in Global News Feed | Comments Off on Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Gritstone bio Announces Workforce Reduction 

Posted: March 1, 2024 at 2:45 am

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study.

More here:
Gritstone bio Announces Workforce Reduction 

Posted in Global News Feed | Comments Off on Gritstone bio Announces Workforce Reduction 

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Posted: March 1, 2024 at 2:45 am

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s financial results.

Visit link:
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Posted in Global News Feed | Comments Off on Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Posted: March 1, 2024 at 2:45 am

-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024-

Read the original:
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Posted: March 1, 2024 at 2:45 am

CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.

See the article here:
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Posted in Global News Feed | Comments Off on Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

ProKidney to Participate in Jefferies Biotech on the Bay Summit

Posted: March 1, 2024 at 2:45 am

WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024.

Read more here:
ProKidney to Participate in Jefferies Biotech on the Bay Summit

Posted in Global News Feed | Comments Off on ProKidney to Participate in Jefferies Biotech on the Bay Summit

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Posted: March 1, 2024 at 2:45 am

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes

Follow this link:
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Posted in Global News Feed | Comments Off on Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Posted: March 1, 2024 at 2:45 am

- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting -

Read this article:
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Posted in Global News Feed | Comments Off on Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Posted: March 1, 2024 at 2:45 am

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.

Read more:
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Posted in Global News Feed | Comments Off on Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Page 8«..78910..2030..»